Scarica l'app Stockscreener
3.5914
1.06%
-0.0386
Precedente Chiudi:
$3.63
Aprire:
$3.62
Volume 24 ore:
16,368
Relative Volume:
0.23
Capitalizzazione di mercato:
$57.09M
Reddito:
-
Utile/perdita netta:
$-23.87M
Rapporto P/E:
-0.1826
EPS:
-19.67
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
+0.04%
1M Prestazione:
+11.53%
6M Prestazione:
+27.81%
1 anno Prestazione:
+4.71%
Intervallo 1D:
$3.50
$3.635
Intervallo di 1 settimana:
$3.50
$3.70
Portata 52W:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Confronta PYPD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.5914 | 60.38M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.65 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.31 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.82 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.46 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.92 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Iniziato | Roth Capital | Buy |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
How analysts rate PolyPid Ltd. stock todayJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
What makes PolyPid Ltd. stock attractive to growth fundsJuly 2025 Setups & Trade Opportunity Analysis Reports - newser.com
Top chart patterns to watch in PolyPid Ltd.Buy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Published on: 2025-11-19 04:16:34 - newser.com
Will PolyPid Ltd. stock outperform growth indexesJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Will PolyPid Ltd. rebound enough to break evenInsider Selling & Intraday High Probability Alerts - newser.com
Why PolyPid Ltd. stock could benefit from AI revolutionMarket Movement Recap & Risk Controlled Swing Trade Alerts - newser.com
What analysts say about PolyPid Ltd stockLong-Term Growth Stocks & Start Small. End Wealthy. - earlytimes.in
Roth Capital Issues Optimistic Estimate for PolyPid Earnings - Defense World
Published on: 2025-11-16 12:50:26 - newser.com
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold - Defense World
PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness - MSN
Using flow based indicators on PolyPid Ltd.July 2025 Summary & Proven Capital Preservation Methods - newser.com
Published on: 2025-11-13 18:14:47 - newser.com
Roth Capital Maintains PolyPid (PYPD) Buy Recommendation - Nasdaq
Is PolyPid Ltd. stock undervalued vs historical averagesJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
PolyPid (PYPD) Sees Price Target Cut by Roth Capital | PYPD Stoc - GuruFocus
PolyPid Ltd. (NASDAQ:PYPD) Q3 2025 Earnings Call Transcript - Insider Monkey
PolyPid price target lowered to $9 from $10 at Roth Capital - TipRanks
PolyPid Ltd. Advances Towards Key Milestones in 2025 - TipRanks
Published on: 2025-11-12 21:51:34 - newser.com
Leading vs lagging indicators on PolyPid Ltd. performanceOptions Play & Free Growth Oriented Trading Recommendations - newser.com
PolyPid Ltd. Earnings Call: Progress and Potential - TipRanks
PolyPid Ltd (PYPD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges By GuruFocus - Investing.com Canada
Earnings call transcript: PolyPid Q3 2025 shows mixed results, stock dips - Investing.com Australia
Transcript : PolyPid Ltd., Q3 2025 Earnings Call, Nov 12, 2025 - MarketScreener
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
PolyPid : Investor Presentation (29305a) - MarketScreener
PolyPid Keeps Moving Forward Despite Quarterly Losses - Finimize
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results - The Manila Times
PolyPid Ltd. Advances Regulatory Strategy with FDA Pre-NDA Meeting and U.S. Partnership Discussions Following Positive Phase 3 Trial Results - Quiver Quantitative
Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln - MarketScreener
PolyPid (NASDAQ: PYPD) completes IMOH GMP inspection; FDA pre‑NDA set, NDA in 2026 - Stock Titan
PolyPid receives Nasdaq’s non-compliance letter - MSN
Why PolyPid Ltd. stock could rally in 20252025 Market Sentiment & Free Real-Time Market Sentiment Alerts - newser.com
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):